A Single Wave of Monocytes Is Sufficient to Replenish the Long-Term
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Novel Mouse Mutant, Chuzhoi, Has Disruption of Ptk7 Protein and Exhibits Defects in Neural Tube, Heart and Lung Development
Paudyal et al. BMC Developmental Biology 2010, 10:87 http://www.biomedcentral.com/1471-213X/10/87 RESEARCH ARTICLE Open Access The novel mouse mutant, chuzhoi, has disruption of Ptk7 protein and exhibits defects in neural tube, heart and lung development and abnormal planar cell polarity in the ear Anju Paudyal1, Christine Damrau1, Victoria L Patterson1, Alexander Ermakov1,2, Caroline Formstone3, Zuzanna Lalanne1,4, Sara Wells5, Xiaowei Lu6, Dominic P Norris1, Charlotte H Dean1, Deborah J Henderson7, Jennifer N Murdoch1,8* Abstract Background: The planar cell polarity (PCP) signalling pathway is fundamental to a number of key developmental events, including initiation of neural tube closure. Disruption of the PCP pathway causes the severe neural tube defect of craniorachischisis, in which almost the entire brain and spinal cord fails to close. Identification of mouse mutants with craniorachischisis has proven a powerful way of identifying molecules that are components or regulators of the PCP pathway. In addition, identification of an allelic series of mutants, including hypomorphs and neomorphs in addition to complete nulls, can provide novel genetic tools to help elucidate the function of the PCP proteins. Results: We report the identification of a new N-ethyl-N-nitrosourea (ENU)-induced mutant with craniorachischisis, which we have named chuzhoi (chz). We demonstrate that chuzhoi mutant embryos fail to undergo initiation of neural tube closure, and have characteristics consistent with defective convergent extension. These characteristics include a broadened midline and reduced rate of increase of their length-to-width ratio. In addition, we demonstrate disruption in the orientation of outer hair cells in the inner ear, and defects in heart and lung development in chuzhoi mutants. -
PTK7 Expression in Triple-Negative Breast Cancer
ANTICANCER RESEARCH 33: 3759-3764 (2013) PTK7 Expression in Triple-negative Breast Cancer BEYHAN ATASEVEN1,2, REGINA ANGERER1, RONALD KATES3, ANGELA GUNESCH1, PJOTR KNYAZEV4, BERNHARD HÖGEL5, CLEMENS BECKER5, WOLFGANG EIERMANN6 and NADIA HARBECK7 1Department of Gynecology and Obstetrics, Red Cross Women’s Hospital, Munich, Germany; 2Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany; 3Breast Center, Department of Gynecology and Obstetrics Maistrasse Campus, Ludwig Maximilian University Munich, Munich, Germany; 4Department of Molecular Biology, Max Planck Institute of Biochemistry, Martinsried, Germany; 5Department of Pathology, Red Cross Women’s Hospital Munich, Munich, Germany; 6Department of Gynecology and Oncology, Interdiscipilnary Oncology Center Munich, Germany; 7Breast Center, Department of Gynecology and Obstetrics, Großhadern Campus, Ludwig Maximilian University Munich, Munich, Germany Abstract. Background: Protein tyrosine kinase-7 (PTK7) immunoglobulin-like loops, a transmenbrane domain and an plays an important role in cancer. Our aim was to evaluate inactive catalytic tyrosine kinase domain (2, 3). PTK7 seems PTK7 in triple-negative breast cancer (TNBC). Materials to be highly involved in the WNT (named after the Drosophilia and Methods: PTK7 Expression was assessed by Wingless (Wg) and the mouse Int-1 genes)-pathways (4), which immunohistochemistry (IHC) in 133 patients with TNBC. again represent key pathways for epithelial mesenchymal Expression levels were correlated with clinicopathological transition (EMT) and play important roles in cancer (5-8). A features and survival, taking chemotherapy into account. potential impact of PTK7 expression has been studied in Results: Positive PTK7 expression was detected in 28.6% of several malignancies, including colon, lung, gastric and breast tumors. In the total population, no significant difference was cancer, acute myeloid leukemia and liposarcoma (9-15). -
Regulation of Macrophage Development and Function in Peripheral Tissues
REVIEWS Regulation of macrophage development and function in peripheral tissues Yonit Lavin, Arthur Mortha, Adeeb Rahman and Miriam Merad Abstract | Macrophages are immune cells of haematopoietic origin that provide crucial innate immune defence and have tissue-specific functions in the regulation and maintenance of organ homeostasis. Recent studies of macrophage ontogeny, as well as transcriptional and epigenetic identity, have started to reveal the decisive role of the tissue stroma in the regulation of macrophage function. These findings suggest that most macrophages seed the tissues during embryonic development and functionally specialize in response to cytokines and metabolites that are released by the stroma and drive the expression of unique transcription factors. In this Review, we discuss how recent insights into macrophage ontogeny and macrophage–stroma interactions contribute to our understanding of the crosstalk that shapes macrophage function and the maintenance of organ integrity. Mononuclear phagocyte Macrophages are key components of the innate immune characterized the transcriptional and epigenetic pro- system system that reside in tissues, where they function as grammes of tissue-resident macrophages and revealed (MPS). A group of bone immune sentinels. They are uniquely equipped to sense the extent of diversity in these populations1,8. In addi- marrow-derived cells and respond to tissue invasion by infectious microorgan- tion to differences in ontogeny, locally derived tissue (monocytes, macrophages and isms and tissue -
Ptk7-Deficient Mice Have Decreased Hematopoietic Stem Cell Pools As a Result of Deregulated Proliferation and Migration
Ptk7-Deficient Mice Have Decreased Hematopoietic Stem Cell Pools as a Result of Deregulated Proliferation and Migration This information is current as Anne-Catherine Lhoumeau, Marie-Laure Arcangeli, Maria of September 24, 2021. De Grandis, Marilyn Giordano, Jean-Christophe Orsoni, Frédérique Lembo, Florence Bardin, Sylvie Marchetto, Michel Aurrand-Lions and Jean-Paul Borg J Immunol 2016; 196:4367-4377; Prepublished online 18 April 2016; Downloaded from doi: 10.4049/jimmunol.1500680 http://www.jimmunol.org/content/196/10/4367 Supplementary http://www.jimmunol.org/content/suppl/2016/04/16/jimmunol.150068 http://www.jimmunol.org/ Material 0.DCSupplemental References This article cites 55 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/196/10/4367.full#ref-list-1 Why The JI? Submit online. by guest on September 24, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright -
Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) Through Multikinase Inhibition Jessica D
Published OnlineFirst February 9, 2018; DOI: 10.1158/1078-0432.CCR-17-1928 Cancer Therapy: Preclinical Clinical Cancer Research Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition Jessica D. Lang1,William P.D. Hendricks1, Krystal A. Orlando2, Hongwei Yin1, Jeffrey Kiefer1, Pilar Ramos1, Ritin Sharma3, Patrick Pirrotte3, Elizabeth A. Raupach1,3, Chris Sereduk1, Nanyun Tang1, Winnie S. Liang1, Megan Washington1, Salvatore J. Facista1, Victoria L. Zismann1, Emily M. Cousins4, Michael B. Major4, Yemin Wang5, Anthony N. Karnezis5, Aleksandar Sekulic1,6, Ralf Hass7, Barbara C. Vanderhyden8, Praveen Nair9, Bernard E. Weissman2, David G. Huntsman5,10, and Jeffrey M. Trent1 Abstract Purpose: Small cell carcinoma of the ovary, hypercalcemic type three SWI/SNF wild-type ovarian cancer cell lines. We further (SCCOHT) is a rare, aggressive ovarian cancer in young women identified ponatinib as the most effective clinically approved that is universally driven by loss of the SWI/SNF ATPase subunits RTK inhibitor. Reexpression of SMARCA4 was shown to confer SMARCA4 and SMARCA2. A great need exists for effective targeted a 1.7-fold increase in resistance to ponatinib. Subsequent therapies for SCCOHT. proteomic assessment of ponatinib target modulation in Experimental Design: To identify underlying therapeutic vul- SCCOHT cell models confirmed inhibition of nine known nerabilities in SCCOHT, we conducted high-throughput siRNA ponatinib target kinases alongside 77 noncanonical ponatinib and drug screens. Complementary proteomics approaches pro- targets in SCCOHT. Finally, ponatinib delayed tumor dou- filed kinases inhibited by ponatinib. Ponatinib was tested for bling time 4-fold in SCCOHT-1 xenografts while reducing efficacy in two patient-derived xenograft (PDX) models and one final tumor volumes in SCCOHT PDX models by 58.6% and cell-line xenograft model of SCCOHT. -
Progress in Understanding the Pathogenesis of Langerhans Cell Histiocytosis: Back to Histiocytosis X?
review Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Marie-Luise Berres,1,2,3,4 Miriam Merad1,2,3 and Carl E. Allen5,6 1Department of Oncological Sciences, Mount Sinai School of Medicine, 2Tisch Cancer Institute, Mount Sinai School of Medicine, 3Immunology Institute, Mount Sinai School of Medicine, New York, NY, USA, 4Department of Internal Medicine III, University Hospital, RWTH Aachen, Aachen, Germany, 5Texas Children’s Cancer Center, and 6Baylor College of Medicine, Houston, TX, USA Summary Langerhans cell histiocytosis (LCH) is the most common his- tiocytic disorder, arising in approximately five children per Langerhans cell histiocytosis (LCH), the most common million, similar in frequency to paediatric Hodgkin lym- histiocytic disorder, is characterized by the accumulation of phoma and acute myeloid leukaemia (AML) (Guyot-Goubin CD1A+/CD207+ mononuclear phagocytes within granuloma- et al, 2008; Stalemark et al, 2008; Salotti et al, 2009). The tous lesions that can affect nearly all organ systems. Histori- median age of presentation is 30 months, though LCH is cally, LCH has been presumed to arise from transformed or reported in adults in approximately one adult per million, pathologically activated epidermal dendritic cells called Lan- both as unrecognized chronic paediatric disease and de novo gerhans cells. However, new evidence supports a model in disease (Baumgartner et al, 1997). There are occasional which LCH occurs as a consequence of a misguided differen- reports of affected non-twin siblings and multiple cases in tiation programme of myeloid dendritic cell precursors. one family, though it is not clear if this is significantly more Genetic, molecular and functional data implicate activation frequent than one would expect by chance (Arico et al, of the ERK signalling pathway at critical stages in myeloid 2005). -
Molecular Regulation of Janus Kinases (Jaks) Focus on the Pseudokinase Domain
JUULI RAIVOLA Molecular Regulation of Janus Kinases (JAKs) Focus on the Pseudokinase Domain Tampere University Dissertations 366 7DPSHUH8QLYHUVLW\'LVVHUWDWLRQV -88/,5$,92/$ 0ROHFXODU5HJXODWLRQRI-DQXV.LQDVHV -$.V )RFXVRQWKH3VHXGRNLQDVH'RPDLQ $&$'(0,&',66(57$7,21 7REHSUHVHQWHGZLWKWKHSHUPLVVLRQRI WKH)DFXOW\RI0HGLFLQHDQG+HDOWK7HFKQRORJ\ RI7DPSHUH8QLYHUVLW\ IRUSXEOLFGLVFXVVLRQLQ$UYRYlpön NDWX7DPSHUH RQ-DQXDU\DWR¶FORFN $&$'(0,&',66(57$7,21 7DPSHUH8QLYHUVLW\)DFXOW\RI0HGLFLQHDQG+HDOWK7HFKQRORJ\ )LQODQG Responsible 3URIHVVRU2OOL6LOYHQQRLQHQ supervisor 7DPSHUH8QLYHUVLW\ and Custos )LQODQG Pre-examiners 3URIHVVRU-DUL<OlQQH 'RFHQW9LYHN6KDUPD 8QLYHUVLW\RI-\YlVN\Ol 8QLYHUVLW\RI+HOVLQNL )LQODQG )LQODQG Opponent 3URIHVVRU6WHIDQ1&RQVWDQWLQHVFX 8QLYHUVLWpFDWKROLTXHGH/RXYDLQ %HOJLXP 7KHRULJLQDOLW\RIWKLVWKHVLVKDVEHHQFKHFNHGXVLQJWKH7XUQLWLQ2ULJLQDOLW\&KHFN VHUYLFH &RS\ULJKWDXWKRU &RYHUGHVLJQ5RLKX,QF ,6%1 SULQW ,6%1 SGI ,661 SULQW ,661 SGI KWWSXUQIL851,6%1 3XQD0XVWD2\±<OLRSLVWRSDLQR -RHQVXX To my Family i ii TIIVISTELMÄ JAK-STAT-(vapaasti suomennettuna Janus-kinaasi - signaalinvälittäjä ja transkriptioaktivaattori) reitti välittää yli 50 sytokiinin signaaleja, jotka säätelevät solun selviytymistä, jakaantumista, migraatiota, geeniekspressiota, sekä muita elintärkeitä prosesseja kuten immuunivastetta. Siksi myös virheellisesti toimiva JAK- STAT signalointi aikaansaa vakavia seurauksia. Aktivoivat JAK-mutaatiot aiheuttavat hematologisia syöpiä sekä myeloproliferatiivisia tauteja, kun taas vajaatoimintainen JAK-signalointi voi johtaa muun muassa vakavaan -
Epidermal Macrophage Induction, and Langerhans Cell Depletion (Photoimmunology/Ozone Depletion/Contact Sensitivity/T Lymphocytes/Antigen Presenting Cells) K
Proc. Nati. Acad. Sci. USA Vol. 89, pp. 8497-8501, September 1992 Immunology UV exposure reduces immunization rates and promotes tolerance to epicutaneous antigens in humans: Relationship to dose, CDla-DR+ epidermal macrophage induction, and Langerhans cell depletion (photoimmunology/ozone depletion/contact sensitivity/T lymphocytes/antigen presenting cells) K. D. COOPER*t*, L. OBERHELMAN*, T. A. HAMILTON*, 0. BAADSGAARD*§, M. TERHUNE*, G. LEVEE*, T. ANDERSON*t, AND H. KOREN¶ *Immunodermatology Unit, Department of Dermatology, University of Michigan, Ann Arbor, MI 48109; tVeterans Administration Hospital, Ann Arbor, MI 48105; and 'Health Effects Research Labs, Environmental Protection Agency, Chapel Hill, NC 27711 Communicated by Thomas M. Donahue, May 1, 1992 ABSTRACT Increasing UVB radiation at the earth's sur- tibility of UV-exposed mice and the unresponsiveness of face might have adverse effects on in vivo immunologic responses UV-exposed mice to contact allergens were found to be due in humans. We prospectively randomized subjects to test to antigen-specific suppressor T lymphocytes (12, 13). whether epicutaneous immunization is altered by prior admin- UV regulation of murine contact sensitivity has held up istration of biologically equalized doses of UV radiation. Mul- well as a model of immunologic events occurring in photo- tiple doses of antigens on upper inner arm skin (UV protected) carcinogenesis. Epidermal Langerhans cells, an antigen pre- were used to elicit contact sensitivity responses, which were senting population of dendritic cell lineage present in the quantitated by measuring increases in skin thickness. If a dose epidermis (14), have a potent capacity to initiate contact of UVB sufficient to induce redness (erythemagenic) was ad- sensitivity reactions (15, 16), as well as tumor rejection (17). -
Langerhans Cell Langhans Cell
1 Q Ocular-Surface Immunology The names of these two cell types are easily confused—what are they? This one is: --A type of dendritic cell residing in the ocular surface epithelium --An antigen-presenting cell (APC) --Described as the ‘immune sentinels of the ocular surface’ Langerhans cell This one is: --A type of giant cell found in granulomas --Associated with TB --Horseshoe-like arrangement of nuclei Langhans cell 2 A Ocular-Surface Immunology The names of these two cell types are easily confused—what are they? This one is: --A type of dendritic cell residing in the ocular surface epithelium --An antigen-presenting cell (APC) --Described as the ‘immune sentinels of the ocular surface’ Langerhans cell This one is: --A type of giant cell found in granulomas --Associated with TB --Horseshoe-like arrangement of nuclei Langhans cell 3 Ocular-Surface Immunology The names of these two cell types are easily confused—what are they? This one is: --A type of dendritic cell residing in the ocular surface epithelium --An antigen-presenting cell (APC) --Described as the ‘immune sentinels of the ocular surface’ Langerhans cell The … This one is: ER --A type of giant cell found in granulomas --Associated with TB --Horseshoe-like arrangement of nuclei Langhans cell 4 Ocular-Surface Immunology The names of these two cell types are easily confused—what are they? This one is: --A type of dendritic cell residing in the ocular surface epithelium --An antigen-presenting cell (APC) --Described as the ‘immune sentinels of the ocular surface’ Langerhans cell -
Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
Review Targeting Cancer Stem Cells in Triple‐Negative Breast Cancer So‐Yeon Park 1,2, Jang‐Hyun Choi 1 and Jeong‐Seok Nam 1,2,* 1 School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea 2 Cell Logistics Research Center, Gwangju Institute of Science and Technology, Gwangju 61005, Korea * Correspondence: [email protected]; Tel.: +82‐62‐715‐2893; Fax: +82‐62‐715‐2484 Received: 11 June 2019; Accepted: 04 July 2019; Published: 9 July 2019 Abstract: Triple‐negative breast cancer (TNBC) is a highly aggressive form of breast cancer that lacks targeted therapy options, and patients diagnosed with TNBC have poorer outcomes than patients with other breast cancer subtypes. Emerging evidence suggests that breast cancer stem cells (BCSCs), which have tumor‐initiating potential and possess self‐renewal capacity, may be responsible for this poor outcome by promoting therapy resistance, metastasis, and recurrence. TNBC cells have been consistently reported to display cancer stem cell (CSC) signatures at functional, molecular, and transcriptional levels. In recent decades, CSC‐targeting strategies have shown therapeutic effects on TNBC in multiple preclinical studies, and some of these strategies are currently being evaluated in clinical trials. Therefore, understanding CSC biology in TNBC has the potential to guide the discovery of novel therapeutic agents in the future. In this review, we focus on the self‐renewal signaling pathways (SRSPs) that are aberrantly activated in TNBC cells and discuss the specific signaling components that are involved in the tumor‐initiating potential of TNBC cells. Additionally, we describe the molecular mechanisms shared by both TNBC cells and CSCs, including metabolic plasticity, which enables TNBC cells to switch between metabolic pathways according to substrate availability to meet the energetic and biosynthetic demands for rapid growth and survival under harsh conditions. -
Congenital Self-Healing Reticulohistiocytosis: an Underreported Entity
Congenital Self-healing Reticulohistiocytosis: An Underreported Entity Michael Kassardjian, DO; Mayha Patel, DO; Paul Shitabata, MD; David Horowitz, DO PRACTICE POINTS • Langerhans cell histiocytosis (LCH) is believed to occur in 1:200,000 children and tends to be underdiagnosed, as some patients may have no symptoms while others have symptoms that are misdiagnosed as other conditions. • Patients with L CH usually should have long-term follow-up care to detect progression or complications of the disease or treatment. copy not Langerhans cell histiocytosis (LCH), also known angerhans cell histiocytosis (LCH), also as histiocytosis X, is a group of rare disorders known as histiocytosis X, is a general term that characterized by the continuous replication of describes a group of rare disorders characterized L 1 a particular white blood cell called LangerhansDo by the proliferation of Langerhans cells. Central cells. These cells are derived from the bone mar- to immune surveillance and the elimination of for- row and are found in the epidermis, playing a large eign substances from the body, Langerhans cells are role in immune surveillance and the elimination of derived from bone marrow progenitor cells and found foreign substances from the body. Additionally, in the epidermis but are capable of migrating from Langerhans cells are capable of migrating from the the skin to the lymph nodes. In LCH, these cells skin to lymph nodes, and in LCH, these cells begin congregate on bone tissue, particularly in the head to congregate on the bone, particularly in the head and neck region, causing a multitude of problems.2 and neck region, causingCUTIS a multitude of problems. -
Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.